Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
View Patent ↗The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.
1. A method of inhibiting production of amyloid precursor protein in a mammalian subject in need thereof, comprising administering transdermally to the mammalian subject an effective amount of a pharmaceutical composition comprising (+)-phenserine.
2. The method of claim 1 , wherein the dosage of (+)-phenserine is from about 0.1 mg/kg to about 100 mg/kg of body weight.
3. The method of claim 2 , wherein the dosage of (+)-phenserine is from about 0.1 mg/kg to about 20 mg/kg of body weight.
4. The method of claim 3 , wherein the dosage of (+)-phenserine is from about 0.1 mg/kg to about 5 mg/kg of body weight.
5. The method of claim 1 , wherein the pharmaceutical composition is administered daily to the mammalian subject.
6. The method of claim 5 , wherein the pharmaceutical composition is administered once daily to the mammalian subject.
7. The method of claim 5 , wherein the pharmaceutical composition is administered twice daily to the mammalian subject.
8. The method of claim 1 , wherein the pharmaceutical composition comprises a slow release system.
9. The method of claim 1 , wherein the pharmaceutical composition comprises a sustained release system.
10. The method of claim 1 , wherein the pharmaceutical composition is administered by a polymer based delivery system.
11. The method of claim 1 , wherein the pharmaceutical composition comprises (+)-phenserine tartrate.
12. The method of claim 1 , wherein the mammalian subject is human.
13. A method of treating dementia in a mammalian subject in need thereof, comprising administering transdermally to the mammalian subject an effective amount of a pharmaceutical composition comprising (+)-phenserine.
14. The method of claim 13 , wherein the dementia is Alzheimer's Disease.
15. The method of claim 13 , wherein the dosage of (+)-phenserine is from about 0.1 mg/kg to about 100 mg/kg of body weight.
16. The method of claim 15 , wherein the dosage of (+)-phenserine is from about 1 mg/kg to about 20 mg/kg of body weight.
17. The method of claim 16 , wherein the dosage of (+)-phenserine is from about 1 mg/kg to about 5 mg/kg of body weight.
18. The method of claim 13 , wherein the pharmaceutical composition is administered daily to the mammalian subject.
19. The method of claim 18 , wherein the pharmaceutical composition is administered once daily to the mammalian subject.
20. The method of claim 18 , wherein the pharmaceutical composition is administered twice daily to the mammalian subject.
21. The method of claim 13 , wherein the pharmaceutical composition comprises a slow release system.
22. The method of claim 13 , wherein the pharmaceutical composition comprises a sustained release system.
23. The method of claim 13 , wherein the pharmaceutical composition is administered by a polymer based delivery system.
24. The method of claim 13 , wherein the pharmaceutical composition comprises (+)-phenserine tartrate.
25. The method of claim 13 , wherein the mammalian subject is human.